Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2-4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL).

IF 4.4 3区医学 Q1 ECONOMICS

PharmacoEconomics Pub Date : 2024-06-01 Epub Date: 2024-01-27 DOI:10.1007/s40273-024-01355-1

Xiuqin Xiong, Natalie Carvalho, Li Huang, Gang Chen, Renee Jones, Nancy Devlin, Brendan Mulhern, Kim Dalziel

{"title":"Psychometric Properties of Child Health Utility 9D (CHU9D) Proxy Version Administered to Parents and Caregivers of Children Aged 2-4 Years Compared with Pediatric Quality of Life Inventory™ (PedsQL).","authors":"Xiuqin Xiong, Natalie Carvalho, Li Huang, Gang Chen, Renee Jones, Nancy Devlin, Brendan Mulhern, Kim Dalziel","doi":"10.1007/s40273-024-01355-1","DOIUrl":null,"url":null,"abstract":"Objective: This study examines the psychometric properties of the Child Health Utility 9D (CHU9D) proxy version administered to parents/caregivers of 2-4-year-old Australian children compared with Pediatric Quality of Life Inventory™ version 4.0 (PedsQL).Methods: Data collected in 2021/2022 from parents/caregivers of 2-4-year-olds from the Australian pediatric multi-instrument comparison study were used. Feasibility, ceiling/floor effects, test-retest reliability, convergent validity, known-group validity, and responsiveness were assessed.Results: A total of 842 caregivers completed the survey at baseline, with 513 completing the follow-up survey. The CHU9D did not demonstrate ceiling effects in the sample with special health care needs, with only 6% of respondents reporting best levels for all nine dimensions. CHU9D correlated with PedsQL moderately-to-strongly between comparable items (correlation coefficients 0.34-0.70). CHU9D was able to differentiate between groups with known health differences with moderate-to-large effect sizes (Cohen's d 0.58-2.03). Moderate test-retest reliability was found for CHU9D in those reporting no health change at a 2-day follow-up (ICC 0.52). A standard response mean (SRM) of 0.25-0.44 was found for children with changes in general health and a SRM of 0.72-0.82 for children who reported worsened health when developing new illnesses, indicating small-to-large responsiveness according to different definitions of health changes. Compared with PedsQL, CHU9D had similar known-group validity and responsiveness and slightly poorer test-retest reliability.Conclusion: The CHU9D was found to be valid and reliable to measure health-related quality-of-life in children aged 2-4 years, although with relatively low test-retest reliability in some dimensions. Further development and validation work is warranted.","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"147-161"},"PeriodicalIF":4.4000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169045/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmacoEconomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40273-024-01355-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/27 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study examines the psychometric properties of the Child Health Utility 9D (CHU9D) proxy version administered to parents/caregivers of 2-4-year-old Australian children compared with Pediatric Quality of Life Inventory™ version 4.0 (PedsQL).

Methods: Data collected in 2021/2022 from parents/caregivers of 2-4-year-olds from the Australian pediatric multi-instrument comparison study were used. Feasibility, ceiling/floor effects, test-retest reliability, convergent validity, known-group validity, and responsiveness were assessed.

Results: A total of 842 caregivers completed the survey at baseline, with 513 completing the follow-up survey. The CHU9D did not demonstrate ceiling effects in the sample with special health care needs, with only 6% of respondents reporting best levels for all nine dimensions. CHU9D correlated with PedsQL moderately-to-strongly between comparable items (correlation coefficients 0.34-0.70). CHU9D was able to differentiate between groups with known health differences with moderate-to-large effect sizes (Cohen's d 0.58-2.03). Moderate test-retest reliability was found for CHU9D in those reporting no health change at a 2-day follow-up (ICC 0.52). A standard response mean (SRM) of 0.25-0.44 was found for children with changes in general health and a SRM of 0.72-0.82 for children who reported worsened health when developing new illnesses, indicating small-to-large responsiveness according to different definitions of health changes. Compared with PedsQL, CHU9D had similar known-group validity and responsiveness and slightly poorer test-retest reliability.

Conclusion: The CHU9D was found to be valid and reliable to measure health-related quality-of-life in children aged 2-4 years, although with relatively low test-retest reliability in some dimensions. Further development and validation work is warranted.

查看原文本刊更多论文

儿童健康效用 9D (CHU9D) 代理版与儿科生活质量量表 (PedsQL™) 的心理测量特性比较：儿童健康效用 9D (CHU9D) 代理版由 2-4 岁儿童的父母和看护者使用。

研究目的本研究探讨了儿童健康效用9D（CHU9D）替代版与儿科生活质量量表™4.0版（PedsQL）的心理测量特性，前者是由澳大利亚2-4岁儿童的父母/监护人实施的：方法：采用 2021/2022 年从澳大利亚儿科多工具比较研究中收集的 2-4 岁儿童父母/监护人的数据。对可行性、天花板/地板效应、重复测试可靠性、收敛有效性、已知组有效性和响应性进行了评估：共有 842 名护理人员完成了基线调查，其中 513 人完成了后续调查。在有特殊健康护理需求的样本中，CHU9D 没有显示出天花板效应，只有 6% 的受访者在所有九个维度上都达到了最佳水平。在可比项目之间，CHU9D 与 PedsQL 的相关性从中等到较强（相关系数为 0.34-0.70）。CHU9D 能够区分具有已知健康差异的群体，其效应大小为中度到大型（Cohen's d 0.58-2.03）。在 2 天的随访中，CHU9D 在报告健康状况无变化的人群中发现了中等程度的重测可靠性（ICC 0.52）。一般健康状况有变化的儿童的标准反应平均值（SRM）为 0.25-0.44，而报告健康状况恶化的儿童在罹患新疾病时的标准反应平均值（SRM）为 0.72-0.82，这表明根据健康状况变化的不同定义，标准反应平均值从低到高不等。与PedsQL相比，CHU9D的已知组有效性和反应性相似，但测试再测可靠性稍差：CHU9D在测量2-4岁儿童与健康相关的生活质量方面具有有效性和可靠性，但在某些方面的重测可靠性相对较低。有必要进行进一步的开发和验证工作。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PharmacoEconomics 医学-药学

CiteScore

8.10

自引率

9.10%

发文量

审稿时长

6-12 weeks

期刊介绍： PharmacoEconomics is the benchmark journal for peer-reviewed, authoritative and practical articles on the application of pharmacoeconomics and quality-of-life assessment to optimum drug therapy and health outcomes. An invaluable source of applied pharmacoeconomic original research and educational material for the healthcare decision maker. PharmacoEconomics is dedicated to the clear communication of complex pharmacoeconomic issues related to patient care and drug utilization. PharmacoEconomics offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article.